Atinvicitinib is a selective Janus kinase 1 (JAK1) inhibitor developed by Merck Animal Health as a veterinary medicine for the treatment of atopic dermatitis and allergic dermatitis in dogs. It is marketed under the brand name NUMELVI™ and was approved by the European Commission in 2025. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include 2169273-59-8. Its PubChem CID is 135138184.
Atinvicitinib
| CAS No | 2169273-59-8 |
|---|---|
| Molecular Formula | C16H17FN6O3 |
| Molecular Weight | 360.34 g/mol |
| Synonyms | 1-[(3R,4S)-4-cyanooxan-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]pyrazole-4-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Atinvicitinib is a selective Janus kinase 1 (JAK1) inhibitor developed by Merck Animal Health as a veterinary medicine for the treatment of atopic dermatitis and allergic dermatitis in dogs.
The listed CAS number is 2169273-59-8.
The listed molecular formula is C16H17FN6O3.
The listed molecular weight is 360.34 g/mol.
1-[(3R,4S)-4-cyanooxan-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridinyl)amino]pyrazole-4-carboxamide.
The source lists 2169273-59-8.